Reverse phase protein arrays: mapping the path towards personalized medicine

Area of Science:

• Biotechnology
• Molecular Biology
• Cancer Research

Background:

• Reverse phase protein array (RPPA) technology combines principles from miniaturized immunoassays and gene microarrays.
• RPPA enables quantification of proteins and their post-translational modifications in various biological samples.
• The increasing need for personalized therapies drives demand for precise molecular profiling technologies.

Purpose of the Study:

• To review the application and significance of RPPA technology in cancer research.
• To highlight RPPA's role in deciphering protein signaling networks.
• To explore RPPA's emerging utility in personalized cancer medicine.

Main Methods:

• Utilizes principles of immunoassays and microarray technology.
• Provides high-throughput or low-throughput quantification of proteins and their modifications.
• Employs arrays for quantifying large sample numbers under identical conditions.

Main Results:

• RPPA is used in clinical trials to profile protein signaling pathways in tumors and in patients undergoing treatment.
• The technology facilitates comparison of signaling pathway states temporally, between patients, or within the same patient over time.
• RPPA is being validated for low-throughput analysis of individual patient samples for personalized medicine.

Conclusions:

• RPPA is a fundamental tool for understanding protein signaling networks in cancer.
• RPPA's adaptability supports both large-scale profiling and individualized patient sample analysis.
• The technology is crucial for advancing personalized cancer medicine by enabling molecular portrait-based treatment strategies.